Nutriband Inc. (NTRB) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Orlando, FL, アメリカ. 現CEOは Gareth Sheridan.
NTRB を有する IPO日 2021-10-01, 13 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $49.67M.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
